Germany’s Merck KGaA has presented longer-term results from the global Phase III MANEUVER trial evaluating pimicotinib at the ...

DESTINY-Breast05 Phase III trial data has shown that Enhertu (trastuzumab deruxtecan) led to a highly statistically ...

Roche late Friday released results from two Phase III studies - dubbed MEERKAT and SANDCAT - evaluating the efficacy and ...

Isotope Technologies Munich (ITM) has announced a higher objective response rate (ORR) and prolonged median progression-free ...

More positive data has been presented at the ESMO Congress on Enhertu (trastuzumab deruxtecan), a specifically engineered ...

USA-based Praxis Precision Medicines, a biopharma translating genetic insights into the development of therapies for central ...

New York-based Immunai, a biotech that uses single-cell genomics and machine learning to discover and improve development of ...

Shares of China’s Hansoh Pharmaceutical edged up 2% to HK$36.50 as it announced a license agreement with Roche for HS-20110, ...

The European Medicine Agency’s (EMA) human medicines committee (CHMP) recommended two novel medicines for approval at its ...

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has presented new data showing the impact of its PD-L1 inhibitor Imfinzi ...

US hematology specialist Disc Medicine surged 19.7% in after-hours trading Thursday after the company announced it received a ...

Chinese biotech Kelun-Biotech (HKEX: 6990) has gained approval from the National Medical Products Administration for ...